Resolution Therapeutics announces upcoming presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025

Dr Paul Brennan to present on the association of early biomarker modulation with long term clinical outcomes from the MATCH Ph II study of non-engineered macrophages in cirrhosis

– Dr Lara Campana to present on anti-inflammatory and anti-fibrotic effects of regenerative macrophage therapy in models of liver fibrosis

Edinburgh and London, UK, 9 October 2025 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy in inflammatory and fibrotic diseases, today announces two abstracts have been selected for presentation at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025. The conference will take place in Washington D.C., between 7-11 November 2025.

Dr Paul Brennan MD, PhD, Clinical Lecturer in Hepatology, University of Dundee, UK, will present data from the University of Edinburgh’s MATCH 2 clinical trial demonstrating that regenerative macrophage therapy (RMT) is associated with early changes in biomarkers associated with liver function (INR; dMELD), which in turn correlate with much longer survival in patients with advanced cirrhosis. Details below:

Title: Early modulation of INR and MELD after regenerative macrophage therapy is associated with favourable clinical outcomes at three-year follow-up

Publication Number: 2435 

Author: Dr. Paul Brennan, PhD

Date/Time: 8 November 2025, 8:00am – 5:00pm EST

Track: Portal Hypertension and Other Complications of Cirrhosis ("2280-2479")

Dr. Lara Campana, Ph.D., co-founder and Senior Vice President of Research and Translational Science at Resolution will present a poster detailing the preclinical data supporting the anti-inflammatory and anti-fibrotic effects of regenerative macrophage therapies in models of liver fibrosis. Details below:

Title: Assessment of regenerative macrophage therapy pharmacology supports anti-inflammatory and anti-fibrotic effects in preclinical models of liver fibrosis

Publication Number: 3391

Author: Dr Lara Campana, PhD

Date/Time: 9 November 2025, 5:00pm – 6:30pm EST

Track: Liver Fibrogenesis and Non-Parenchymal Cell Biology ("3335-3420")

Members of the Resolution senior leadership team will be attending the conference. Please reach out to set up a meeting to learn more about the Company.